Results 101 to 110 of about 8,219 (198)

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting

Rheumatology and Therapy
Introduction This study aimed to compare the real-world effectiveness of upadacitinib vs. other Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA). Methods Data were extracted from the Adelphi RA Disease Specific Programme™ (DSP),
Peter C. Taylor, Aditi Kadakia, Jack Milligan, Ana Romero, Oliver Howell, Pankaj A. Patel, Sophie Barlow, Roberto Caporali   +7 more
doaj   +1 more source

Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports

Frontiers in Immunology
Upadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis.
Rui Mo, Shuxia Yu, Hongwei Xu, Jinghua Hao   +3 more
doaj   +1 more source

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

Xin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2School of Clinical ...
Lang J, Xiao M, He X, Yang D, Lai L, Wei K   +5 more
core  

Upadacitinib for Alopecia: Current Evidence and Clinical Insights

BACKGROUND: Upadacitinib, a selective Janus kinase (JAK) 1 inhibitor, has demonstrated promising efficacy in alopecia areata (AA), particularly in patients unresponsive to conventional therapies.
Lipner, Shari R., Stirrat, Thomas, Thakker, Sach, Goh, Carolyn, Bejugam, Deeptha   +4 more
core   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2036-2049, October 2026.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment

Journal of Dermatological Treatment
Background Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives To compare ocular outcomes and conjunctival
Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak   +2 more
doaj   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2171-2178, October 2026.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

RMD Open
Introduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed ...
Bruno Fautrel, Philip J Mease, Arthur Kavanaugh, Tsutomu Takeuchi, Peter C Taylor, Louis Bessette, Ralph Lippe, Tianming Gao, Charles Phillips, Andrew Garrison, Diane Caballero   +10 more
doaj   +1 more source